Clinical outcome of children and adults with localized ewing sarcoma: Impact of chemotherapy dose and timing of local therapy

Cancer

Volumn 116, Issue 13, 2010, Pages 3189-3194

  Gupta, Abha A ^a   Pappo, Alberto ^b   Saunders, Natasha ^a   Hopyan, Sevan ^a   Ferguson, Peter ^c   Wunder, Jay ^a   O'Sullivan, Brian ^d   Catton, Charles ^d   Greenberg, Mark ^a   Blackstein, Martin ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Adult; Chemotherapy; Ewing sarcoma; Pediatric; Radiotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BONE RESECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CHILD; CONTROLLED STUDY; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; MIDDLE AGED; SARCOMA, EWING'S;

EID: 77954271838     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25144     Document Type: Article

References (22)

1. Gurney JG, Bulterys M. Malignant bone tumors. Bethesda, MD: National Institutes of Health; 1999.
2. Casillas J. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. NIH Pub. No. 06-5767. Bethesda, MD: National Cancer Institute; 2006.
3. Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: the Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol. 1998; 16:3628-3633.
4. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18:3108-3114.
5. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000; 18:4-11.
6. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348:694-701.
7. Verrill MW, Judson IR, Harmer CL, Fisher C, Thomas JM, Wiltshaw E. Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children? J Clin Oncol. 1997; 15:2611-2621.
8. Fizazi K, Dohollou N, Blay JY, et al. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol. 1998; 16:3736-3743. (Pubitemid 29001524)
9. Hense HW, Ahrens S, Paulussen M, Lehnert M, Jurgens H. Descriptive epidemiology of Ewing's tumor - analysis of German patients from (EI)CESS 1980-1997. Klin Padiatr. 1999; 211:271-275.
10. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009; 27:2536-2541.
11. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 1991; 83:1460-1470.
12. Klaassen R, Sastre-Garau X, Aurias A, et al. [Ewing's sarcoma of bone in adults: an anatomic-clinical study of 30 cases]. Bull Cancer. 1992; 79:161-167.
13. Baldini EH, Demetri GD, Fletcher CD, Foran J, Marcus KC, Singer S. Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg. 1999; 230:79-86. (Pubitemid 30190368)
14. Bacci G, Ferrari S, Comandone A, et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol. 2000; 39:111-116.
15. Martin RC Jr, Brennan MF. Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: predictors of survival? Arch Surg. 2003; 138:281-285.
16. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment - cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008; 26:4385-4393.
17. Womer RB, West DC, Krailo MD, Dickman PS, Pawel B. Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT). Paper presented at American Society of Clinical Oncology, Chicago, Illinois, May 30-June 3, 2008.
18. Dunst J, Schuck A. Role of radiotherapy in Ewing tumors. Pediatr Blood Cancer. 2004; 42:465-470.
19. Li WK, Lane JM, Rosen G, et al. Pelvic Ewing's sarcoma. Advances in treatment. J Bone Joint Surg Am. 1983; 65:738-747. (Pubitemid 13025984)
20. Donati D, Yin J, Di Bella C, et al. Local and distant control in non-metastatic pelvic Ewing's sarcoma patients. J Surg Oncol. 2007; 96:19-25. (Pubitemid 47015444)
21. Yock TI, Krailo M, Fryer CJ, et al. Local control in pelvic Ewing sarcoma: analysis from INT-0091 - a report from the Children's Oncology Group. J Clin Oncol. 2006; 24:3838-3843. (Pubitemid 46655603)
22. Hoffmann C, Ahrens S, Dunst J, et al. Pelvic Ewing sarcoma: a retrospective analysis of 241 cases. Cancer. 1999; 85:869-877. (Pubitemid 29077563)